Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

AB16955

Sigma-Aldrich

Anti-DR4 Antibody, CT

Chemicon®, from rabbit

Sinonimo/i:

TRAIL-R1

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

100 μG
CHF 360.00

CHF 360.00


Spedizione prevista il29 maggio 2025


Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
100 μG
CHF 360.00

About This Item

Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

CHF 360.00


Spedizione prevista il29 maggio 2025


Richiedi un ordine bulk

Origine biologica

rabbit

Livello qualitativo

Forma dell’anticorpo

affinity purified immunoglobulin

Tipo di anticorpo

primary antibodies

Clone

polyclonal

Reattività contro le specie

human

Produttore/marchio commerciale

Chemicon®

tecniche

western blot: suitable

N° accesso NCBI

N° accesso UniProt

Condizioni di spedizione

wet ice

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

Specificità

Apoptosis, or programmed cell death, occurs during normal cellular diffferentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR4 (for death receptor 4) (Pan et al. 1997). The ligand for this novel cell death receptor has been identified and termed TRAIL, which is a new member in TRF family. Therefore, DR4 is also called TRAIL receptor-1 (TRAIL-R1) (Schneider et al. 1997). DR4 is expresssed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates TRAIL induced apoptosis and NF-kB activation in many tissues and cells.

Immunogeno

Epitope: C-terminus
Polyclonal antibody raised against a peptide corresponding to amino acids 427-445 at C-terminus of human DR4 mature protein.

Applicazioni

Detect DR4 using this Anti-DR4 Antibody, C-terminus validated for use in WB.
Research Category
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
Western blot: 1:500-1:1000

Whole cell lysate from HeLa cells can be used as a positive control and a 57 kDa band should be detected.

Optimal working dilutions must be determined by end user.

Stato fisico

Affinity purified immunoglobulin. Liquid in PBS containing 0.02% sodium azide.
Format: Purified

Stoccaggio e stabilità

Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months.

Altre note

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Note legali

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

V Pavet et al.
Cell death & disease, 5, e1043-e1043 (2014-02-01)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/TNFSF10/Apo2L) holds promise for cancer therapy as it induces apoptosis in a large variety of cancer cells while exerting negligible toxicity in normal ones. However, TRAIL can also induce proliferative and migratory signaling in cancer
Sofie Hagelund et al.
Frontiers in cell and developmental biology, 10, 768579-768579 (2022-03-15)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an important mediator of tumor immune surveillance. In addition, its potential to kill cancer cells without harming healthy cells led to the development of TRAIL receptor agonists, which however did not show the
Dmitri V Rozanov et al.
Molecular cancer therapeutics, 8(6), 1515-1525 (2009-06-11)
Successful cancer therapies aim to induce selective apoptosis in neoplastic cells. The current suboptimal efficiency and selectivity drugs have therapeutic limitations and induce concomitant side effects. Recently, novel cancer therapies based on the use of tumor necrosis factor-related apoptosis-inducing ligand
Doaa Tawfik et al.
Frontiers in immunology, 10, 2044-2044 (2019-09-27)
Acquired immune evasion is one of the mechanisms that contributes to the dismal prognosis of cancer. Recently, we observed that different γδ T cell subsets as well as CD8+ αβ T cells infiltrate the pancreatic tissue. Interestingly, the abundance of
Mohammed I Y Elmallah et al.
Oncology reports, 37(6), 3635-3642 (2017-04-26)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, as it can kill tumor cells selectively. In our search of bioactive natural products to overcome TRAIL-resistance, we isolated 47 actinomycete strains from different sediments and seawater samples collected

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.